What is AIM Laboratories?
AIM Laboratories operates as a comprehensive molecular diagnostic laboratory, offering an extensive suite of testing services. Their specialization spans critical areas such as PCR testing for infectious diseases including Covid-19, antibiotic resistance, and respiratory tract infections, alongside pharmacogenomics, women's health, and wound diagnostics. The company is committed to delivering rapid turnaround times and high-quality testing to healthcare providers and corporate clients across the United States, leveraging advanced technology and robust customer support to ensure accurate and timely results that enhance patient care. Their broad test menu also encompasses allergy testing, toxicology, clinical endocrinology, and complex chemistry services.
How much funding has AIM Laboratories raised?
AIM Laboratories has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for AIM Laboratories?
The substantial late-stage funding and major strategic investment signal AIM Laboratories' readiness for significant expansion and market penetration. This capital infusion is likely to fuel advancements in their diagnostic technologies, broaden their service offerings, and enhance their operational capacity to meet growing demand. The company is poised to solidify its competitive advantage by potentially investing in research and development, expanding its geographic reach, and forging new partnerships within the healthcare ecosystem. This strategic financial backing positions AIM Laboratories for sustained growth and innovation in the dynamic field of molecular diagnostics.
See full AIM Laboratories company page
